Standout Papers
Immediate Impact
9 from Science/Nature 61 standout
Citing Papers
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
2023 Standout
Alzheimer's disease: From immunotherapy to immunoprevention
2023 Standout
Works of Ron Keren being referenced
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Ron Keren | 249 | 309 | 257 | 373 | 298 | 17 | 1.1k | |
| Brendon Boot | 336 | 351 | 414 | 525 | 144 | 25 | 1.2k | |
| Srinath N. Bellur | 326 | 393 | 242 | 194 | 169 | 16 | 1.1k | |
| Donna Masterman | 622 | 334 | 360 | 182 | 215 | 16 | 1.2k | |
| Alain Robillard | 517 | 260 | 229 | 614 | 145 | 18 | 1.4k | |
| Luca Rozzini | 563 | 187 | 288 | 344 | 110 | 18 | 1.3k | |
| Hannah Fox | 620 | 279 | 476 | 377 | 124 | 17 | 1.3k | |
| Frederick W. Bylsma | 530 | 359 | 108 | 280 | 276 | 27 | 1.2k | |
| Kent M. Perryman | 590 | 492 | 446 | 225 | 177 | 35 | 1.3k | |
| Yoshitaka Ikejiri | 533 | 401 | 281 | 187 | 187 | 37 | 1.1k | |
| Kari Reinikainen | 613 | 234 | 337 | 171 | 265 | 27 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...